The National Cancer Institute awarded a Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the University of Wisconsin System in the amount of $680,453 for the period of January 1, 2025 to December 31, 2030. The project aims to develop and implement a "fragmentomics" approach using circulating tumor DNA (ctDNA) to monitor the transition between prostate adenocarcinoma and neuroendocrine prostate cancer (NEPC) in patients with metastatic castration-resistant prostate cancer (mCRPC). The key objectives are to: 1) determine if baseline ctDNA fragmentomics scores are prognostic biomarkers in mCRPC, 2) detect diverse mechanisms of androgen receptor signaling inhibitor (ARSI) resistance in longitudinal ctDNA, and 3) evaluate ctDNA fragmentomics biomarkers in the Alliance A031201 clinical trial to identify ARSI resistance and biomarkers of dual ARSI response. The project aims to revolutionize the monitoring and treatment decision-making capabilities for mCRPC patients through a novel, integrated liquid biopsy approach leveraging machine learning.
Generated 3/25/25, 4:52 AM